

WARNING LETTER

Date: April 6, 2020

TO eric@anandaapothecary.com – Mr. Scott Merrill, Ananda, LLC DBA Ananda
Apothecary
4735 Walnut St Ste E
Boulder, CO 80301-2553 US

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address www.anandaessentialoils.com on March 27, 2020 and April 2, 2020, respectively. The FDA has observed that your website offers essential oil products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19¹ in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The .8 (ed).8 (ed)e-1.141 3(an)10.5 (ded)0.5a986 (he)- are(ec)8.8 (t)he Decieus 5178 (ia)10e1 41 3(an6 (s named "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2). The disease caused by the virus has been named "Coronavirus Disease 2019" (COVID-19). On January 31, 2020, the Department of

Sincerely,

Donald D. Ashley
Director
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

Sincerely,

Richard A. Quaresima
Acting Associate Director
Division of Advertising Practices
Federal Trade Commission